By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Cannabis NewsCannabis News
  • Cannabis
  • CBD
  • Science
  • Culture & Arts
  • Cannabis Press Releases
  • More
    • About Maryjanes Post
    • Cannabis Advertising
    • Cannabis Partnerships
Reading: Anebulo Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Share
Aa
Aa
Cannabis NewsCannabis News
Search
  • Topics
    • Business
    • Cannabis
    • Cannabis Tech
    • Culture & Arts
    • Industry Leaders
    • Cannabis Press Releases
  • Topics
    • Business
    • Cannabis
    • Cannabis Tech
    • Culture & Arts
    • Industry Leaders
    • Cannabis Press Releases
  • About Maryjanes Post
    • Ambassador
    • Cannabis Partnerships
Follow US
  • Ad Choices
  • RSS Terms of Service
© 2018 - 2022 MaryJanes Post Media. All Rights Reserved.
Cannabis Press Releases

Anebulo Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Business Wire
Last updated: 2022/05/30 at 7:54 AM
Business Wire Published September 7, 2021
Share
SHARE

AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced that management will be participating in the H.C. Wainwright 23rd Annual Global investment Conference being held virtually on September 13-15, 2021. Management will deliver a company presentation and will be available for one-on-one meetings with investors. The recorded presentation will be available on demand beginning Monday, September 13th on the Investors section of Anebulo’s website.

About Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of acute cannabinoid intoxication within one hour of administration. Clinical trials completed to date have shown that ANEB-001 is rapidly absorbed, well tolerated and leads to weight loss, an effect that is consistent with central cannabinoid receptor type 1 antagonism. For further information about Anebulo, please visit www.anebulo.com.

Cannabis Media & PR

Contacts

Anebulo Pharmaceuticals, Inc.
Rex Merchant

Chief Financial Officer

(512) 598-0931

[email protected]

LHA Investor Relations
Yvonne Briggs

(310) 691-7100

[email protected]

You Might Also Like

Cookies Unites With Social Equity Partner To Open Its First Illinois Cannabis Retail Store

Botanical Sciences Leads the Way as Georgia Becomes First State to Dispense Medical Cannabis at Independent Pharmacies

Leafly Regains Compliance with Nasdaq Minimum Bid Price Requirement

Manatt Expands National Cannabis Practice With New York State’s Top Regulator

“The Future Is Bright” With Opportunities to Grow: BioAlberta’s State of the Industry Reports on Alberta’s Life Sciences and Healthcare Industry

TAGGED: Business Wire
Business Wire September 7, 2021
Share This Article
Twitter Reddit Email Copy Link
Previous Article Global Medical Cannabis Market (2021 to 2026) – Industry Trends, Share, Size, Growth, Opportunity and Forecasts – ResearchAndMarkets.com
Next Article China CBD Regulatory Report 2021: Yunnan and Heilongjiang Regulations Evolving – ResearchAndMarkets.com

Cannabis News and More

Work with an experienced cannabis media firm to provide your brand with the exposure it needs.

Cannabis Topics

  • Cannabis
  • Business
  • CBD
  • Cannabis Science
  • Culture & Arts

Company

  • About Maryjanes Post
  • Contact Cannabis Media
  • Contributor Guidelines

Terms of Use

  • TERMS
  • PRIVACY
  • CONTRIBUTOR AGREEMENT
  • DMCA

Resources

  • Write For UsNew
  • Media KitNew
  • Cannabis Advertising
  • Cannabis Partnerships
  • Cannabis Press ReleaseNew
Cannabis NewsCannabis News
Follow US
© 2018 - 2022 MaryJanes Post Media. All Rights Reserved.
  • Ad Choices
  • RSS Terms of Service
Go to mobile version
Welcome Back!

Sign in to your account

Lost your password?